Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase NA 3Phase 3 3Phase 4 1Phase 1 1

Status

Completed 3Unknown 1

Sponsor Class

OTHER 3OTHER_GOV 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 7Lymphoid 6Other hematologic neoplasm 4Gynecologic 4Gastrointestinal 4Breast 4Sarcoma 3Genitourinary 3Dermatologic 3Head & Neck 2Classical hematology 2Plasma cell 1Myeloid 1CNS 1

Conditions

Colorectal Neoplasms 1295Pancreatic Neoplasms 818Carcinoma, Hepatocellular 782Stomach Neoplasms 753Rectal Neoplasms 565Esophageal Neoplasms 452Colonic Neoplasms 414Esophageal Squamous Cell Carcinoma 277Neoplasm Metastasis 263Cholangiocarcinoma 251Liver Neoplasms 219Neoplasms 200Biliary Tract Neoplasms 179Adenocarcinoma Of Esophagus 139Gastrointestinal Stromal Tumors 108Gallbladder Neoplasms 96Adenocarcinoma 94Breast Neoplasms 91Gastrointestinal Neoplasms 89Carcinoma, Non-Small-Cell Lung 87Bile Duct Neoplasms 69Sarcoma 67Lung Neoplasms 64Ovarian Neoplasms 60Anus Neoplasms 59Melanoma 54Uterine Cervical Neoplasms 52Carcinoma 48Digestive System Neoplasms 45Prostatic Neoplasms 40

Interventions

camrelizumab 1Tegafur 1Surgical Procedures, Operative 1Hyperthermic Intraperitoneal Chemotherapy 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Drug-Related Side Effects and Adverse Reactions × Gastrointestinal × Clear all
NCT05355168 2024-12-31

Neoadjuvant CRT Combined With Camrelizumab and Nimotuzumab for Initially Inoperable Patients With Esophageal Carcinoma

Anhui Provincial Hospital

Phase 2 Completed
35 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma, Drug-Related Side Effects and Adverse Reactions

NCT03246321 2019-10-15

CRC-PIPAC

Catharina Ziekenhuis Eindhoven

Phase 2 Completed
20 enrolled
GastrointestinalGynecologic

Appendiceal Neoplasms, Cecal Neoplasms, Intraoperative Complications, Neoplasms, Peritoneal Neoplasms, Postoperative Complications, Colorectal Neoplasms, Drug-Related Side Effects and Adverse Reactions

NCT02447679 2017-02-07

Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrence

Chang Gung Memorial Hospital

Phase 2 Completed
40 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Drug-Related Side Effects and Adverse Reactions

NCT02549911 2015-09-15

HIPEC, Intravenous Chemotherapy and Surgery for the Treatment of Advanced GC With Peritoneal Metastasis

Zhejiang Cancer Hospital

Phase 2 Unknown
40 enrolled
Gastrointestinal

Stomach Neoplasms, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡